Pharmacodynamic-pharmacokinetic Trial, of Slow Release ASA, in the Platelet Functionalism.

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the platelet antiaggregant effect that a chronic treatment with ASA (150 mg) produces,comparing this effect between two formulations of ASA: normal and the one of sustained release, in patients with stable coronary disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rottapharm Spain
• Treatments: Aspirin; Salicylates; Salicylic Acid

Criteria

Inclusion Criteria:

• Previous episodes of myocardial infarction

• Previous episodes of instable angina pectoris

• Previous coronary revascularization

• Significant arterial coronary disease

Exclusion Criteria:

• Patients with other pathologies that requires treatment with other antiaggregants

• Patients in treatment with low molecular weight heparin or oral anticoagulant

• Patients with antecedents of hypersensibility to ASA